quinoxalines has been researched along with Retinal Diseases in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (72.73) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Eliott, D; Kim, LA; Parikh, D | 1 |
| Harrison, AR; Lee, MS; McLoon, LK; Saylor, M | 1 |
| Gul, M; Imrek, S; Ozdemir, G; Tolun, FI | 1 |
| Agey, P; Dong, CJ; Guo, Y; Hare, WA; Wheeler, L | 1 |
| Chai, S; Ellisman, MH; Ju, WK; Kim, KY; Lee, D; Lindsey, JD; Noh, YH; Weinreb, RN | 1 |
| Assia, EI; Belkin, M; Ferencz, JR; Gilady, G; Harel, O | 1 |
| Chowers, I; Farber, MD; Merin, S; Obolensky, A | 1 |
| Lagrèze, WA | 1 |
| de Imperial, JM; Lafuente, MP; Mayor, S; Vidal-Sanz, M; Villegas-Pérez, MP | 1 |
| García-Avilés, A; Lafuente, MP; Miralles de Imperial, J; Sobrado-Calvo, P; Vidal-Sanz, M; Villegas-Pérez, MP | 1 |
| Aguilera, ME; Lafuente, MP; Mayor, S; Miralles de Imperial, J; Vidal-Sanz, M; Villegas-Pérez, MP | 1 |
1 review(s) available for quinoxalines and Retinal Diseases
| Article | Year |
|---|---|
Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review.
Topics: Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Humans; Neuroprotective Agents; Optic Neuropathy, Ischemic; Quinoxalines; Retina; Retinal Diseases; Vitreous Body | 2009 |
2 trial(s) available for quinoxalines and Retinal Diseases
| Article | Year |
|---|---|
Topical brimonidine reduces collateral damage caused by laser photocoagulation for choroidal neovascularization.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Aged; Aged, 80 and over; Brimonidine Tartrate; Choroidal Neovascularization; Double-Blind Method; Female; Humans; Laser Coagulation; Male; Neuroprotective Agents; Ophthalmic Solutions; Pilot Projects; Prospective Studies; Quinoxalines; Retinal Diseases; Visual Acuity | 2005 |
A pilot study of topical treatment with an alpha2-agonist in patients with retinal dystrophies.
Topics: Administration, Topical; Adolescent; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Adult; Aged; Brimonidine Tartrate; Contrast Sensitivity; Electroretinography; Female; Humans; Male; Middle Aged; Patient Compliance; Pilot Projects; Prospective Studies; Quinoxalines; Retinal Degeneration; Retinal Diseases; Retinitis Pigmentosa; Treatment Outcome; Visual Acuity; Visual Fields | 2008 |
8 other study(ies) available for quinoxalines and Retinal Diseases
| Article | Year |
|---|---|
Fibroblast Growth Factor Receptor Inhibitor-Associated Retinopathy.
Topics: Adenocarcinoma; Fluorescein Angiography; Fundus Oculi; Humans; Pyrazoles; Quinoxalines; Receptors, Fibroblast Growth Factor; Retina; Retinal Diseases; Stomach Neoplasms; Tomography, Optical Coherence; Visual Acuity | 2020 |
Retinal oxidative stress induced by intraocular hypertension in rats may be ameliorated by brimonidine treatment and N-acetyl cysteine supplementation.
Topics: Acetylcysteine; Animals; Brimonidine Tartrate; Catalase; Disease Models, Animal; Drug Therapy, Combination; Glutathione Peroxidase; Hyaluronic Acid; Intraocular Pressure; Male; Malondialdehyde; Nitric Oxide; Ocular Hypertension; Oxidative Stress; Quinoxalines; Rats; Rats, Sprague-Dawley; Retinal Diseases; Tonometry, Ocular | 2009 |
Nimodipine enhancement of alpha2 adrenergic modulation of NMDA receptor via a mechanism independent of Ca2+ channel blocking.
Topics: Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Calcium; Calcium Channel Blockers; Excitatory Amino Acid Agonists; Injections; Male; Microscopy, Confocal; N-Methylaspartate; Nimodipine; Patch-Clamp Techniques; Quinoxalines; Rabbits; Rats; Rats, Inbred BN; Receptors, Adrenergic, alpha-2; Receptors, N-Methyl-D-Aspartate; Retinal Diseases; Retinal Ganglion Cells; Vitreous Body | 2010 |
Brimonidine blocks glutamate excitotoxicity-induced oxidative stress and preserves mitochondrial transcription factor a in ischemic retinal injury.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; bcl-2-Associated X Protein; bcl-Associated Death Protein; Brimonidine Tartrate; DNA-Binding Proteins; Glutamic Acid; Ischemia; Mitochondrial Proteins; Oxidative Phosphorylation; Oxidative Stress; Quinoxalines; Rats; Receptors, Adrenergic, alpha-2; Receptors, N-Methyl-D-Aspartate; Retina; Retinal Diseases; Retinal Ganglion Cells; Superoxide Dismutase; Transcription Factors | 2012 |
[Neuroprotection. Bases and possibilities of a future clinical use].
Topics: Adrenergic alpha-Agonists; Animals; Apoptosis; Brimonidine Tartrate; Clinical Trials as Topic; Disease Models, Animal; Dopamine Agents; Eye Diseases; Forecasting; Glaucoma; Humans; Memantine; Neuroprotective Agents; Optic Neuritis; Quinoxalines; Retinal Diseases; Visual Fields | 2001 |
Retinal ganglion cell death induced by retinal ischemia. neuroprotective effects of two alpha-2 agonists.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Cell Count; Cell Death; Cell Survival; Humans; Neuroprotective Agents; Ophthalmic Solutions; Quinoxalines; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Retinal Diseases; Retinal Ganglion Cells | 2001 |
Neuroprotective effects of alpha(2)-selective adrenergic agonists against ischemia-induced retinal ganglion cell death.
Topics: Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Cell Count; Cell Survival; Neuroprotective Agents; Quinoxalines; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Retinal Diseases; Retinal Ganglion Cells | 2001 |
Neuroprotective effects of brimonidine against transient ischemia-induced retinal ganglion cell death: a dose response in vivo study.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Cell Death; Dose-Response Relationship, Drug; Ischemia; Microscopy, Fluorescence; Quinoxalines; Rats; Rats, Sprague-Dawley; Retinal Diseases; Retinal Ganglion Cells; Time Factors | 2002 |